TCGA-AO-A0J9-01A-11R-A034-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 54
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.430
- MYOGENESIS+0.420
- ALLOGRAFT_REJECTION+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- PANCREAS_BETA_CELLS+0.390
- IL6_JAK_STAT3_SIGNALING+0.350
- KRAS_SIGNALING_UP+0.340
- COMPLEMENT+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- ANGIOGENESIS+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- PROTEIN_SECRETION-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.450
- G2M_CHECKPOINT-0.440
- MITOTIC_SPINDLE-0.430
- MTORC1_SIGNALING-0.420
- ANDROGEN_RESPONSE-0.410
- E2F_TARGETS-0.380
- MYC_TARGETS_V1-0.380
- GLYCOLYSIS-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A43S-01A-21R-A23W-07 | — | — | 0.918 |
| 2 | TCGA-AC-A3BB-01A-21R-A19W-07 | — | A | 0.893 |
| 3 | SRR33532813 | — | A | 0.892 |
| 4 | TCGA-GM-A4E0-01A-12R-A266-07 | — | A | 0.892 |
| 5 | dc3154b7-6ae4-446a-8a80-91a86c57cefe | — | — | 0.886 |
| 6 | TCGA-XF-A9SL-01A-11R-A39I-07 | — | — | 0.883 |
| 7 | TCGA-FD-A43U-01A-11R-A23W-07 | — | — | 0.879 |
| 8 | SRR1335707 | GTEX | — | 0.873 |
| 9 | TCGA-Z7-A8R5-01A-42R-A41B-07 | — | B | 0.873 |
| 10 | SRR23303748 | — | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| MYOGENESIS | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |